BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36403965)

  • 1. The genetic alterations of rectal neuroendocrine tumor and indications for therapy and prognosis: a systematic review.
    Li K; Liu Y; Han J; Gui J; Zhang X
    Endocr J; 2023 Feb; 70(2):197-205. PubMed ID: 36403965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets.
    Park HY; Kwon MJ; Kang HS; Kim YJ; Kim NY; Kim MJ; Min KW; Choi KC; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Lee HK
    Hum Pathol; 2019 May; 87():83-94. PubMed ID: 30851333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.
    Laskar RS; Ghosh SK; Talukdar FR
    Mol Carcinog; 2015 Dec; 54(12):1786-95. PubMed ID: 25418895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes.
    Domingo E; Niessen RC; Oliveira C; Alhopuro P; Moutinho C; Espín E; Armengol M; Sijmons RH; Kleibeuker JH; Seruca R; Aaltonen LA; Imai K; Yamamoto H; Schwartz S; Hofstra RM
    Oncogene; 2005 Jun; 24(24):3995-8. PubMed ID: 15782118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
    Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular typing and mutational characterization of rectal neuroendocrine neoplasms.
    Duan X; Zhao M; Yin X; Mi L; Shi J; Li N; Han X; Han G; Wang J; Hou J; Yin F
    Cancer Med; 2023 Aug; 12(15):16207-16220. PubMed ID: 37387515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
    Sclafani F; Wilson SH; Cunningham D; Gonzalez De Castro D; Kalaitzaki E; Begum R; Wotherspoon A; Capdevila J; Glimelius B; Roselló S; Thomas J; Tait D; Brown G; Oates J; Chau I
    Int J Cancer; 2020 Jan; 146(1):94-102. PubMed ID: 31199501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.
    Allen A; Qin ACR; Raj N; Wang J; Uddin S; Yao Z; Tang L; Meyers PA; Taylor BS; Berger MF; Yaeger R; Reidy-Lagunes D; Pratilas CA
    PLoS One; 2019; 14(6):e0217399. PubMed ID: 31158244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Next-Generation Sequencing-Based Multiple Gene Mutation Profiling of Patients with Rectal Adenocarcinoma Receiving or Not Receiving Neoadjuvant Chemoradiotherapy.
    Chang YK; Tseng HH; Leung CM; Lu KC; Tsai KW
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite instability and survival in rectal cancer.
    Samowitz WS; Curtin K; Wolff RK; Tripp SR; Caan BJ; Slattery ML
    Cancer Causes Control; 2009 Nov; 20(9):1763-8. PubMed ID: 19669908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
    Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
    Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
    Erben P; Ströbel P; Horisberger K; Popa J; Bohn B; Hanfstein B; Kähler G; Kienle P; Post S; Wenz F; Hochhaus A; Hofheinz RD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1032-8. PubMed ID: 20947270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.
    Cremolini C; Di Bartolomeo M; Amatu A; Antoniotti C; Moretto R; Berenato R; Perrone F; Tamborini E; Aprile G; Lonardi S; Sartore-Bianchi A; Fontanini G; Milione M; Lauricella C; Siena S; Falcone A; de Braud F; Loupakis F; Pietrantonio F
    Ann Oncol; 2015 Oct; 26(10):2092-7. PubMed ID: 26153495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.